AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NEURIZON THERAPEUTICS LTD

0.056

0.000

Volume:1.07M

Turnover:60.11K

Market Cap:43.92M

PE:-1.93

High:0.057

Open:0.057

Low:0.056

Close:0.056

52wk High:0.165

52wk Low:0.055

Shares:784.22M

Float Shares:351.37M

Volume Ratio:1.90

T/O Rate:0.30%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.029

EPS(LYR):-0.018

ROE:-137.94%

ROA:-45.31%

PB:3.45

PE(LYR):-3.18

Loading ...

Overview Company News Filings

Neurizon Therapeutics Ltd - Total Amount to Be Raised Under Entitlement Offer Is ~a$8.5 Mln

THOMSON REUTERS

Neurizon publishes investor deck outlining NUZ-001 ALS program in HEALEY platform trial

Neurizon says NUZ-001 preclinical data supports multi-pathway protein clearance in ALS models

Neurizon Therapeutics Chief Executive Officer Resigns, Shares Down 13%

MT Newswires Live

Neurizon Therapeutics - Sergio Duchini to Assume Role of Executive Chair Until New CEO Appointed

THOMSON REUTERS

Neurizon Therapeutics - Michael Thurn Resigns as Managing Director and CEO

THOMSON REUTERS

Neurizon Says Pre-Clinical Data Supports Potential of Drug Candidate for Neurodegenerative Disease

MT Newswires Live

Neurizon Doses First Patient With NUZ-001 in HEALEY ALS Platform Trial Regimen I

BUZZ-Australia's Neurizon Therapeutics rises as HY loss narrows, revenue rises

BRIEF-Neurizon Therapeutics Posts Loss For Half Year Attributable Of A$5.5 Million

Neurizon Therapeutics Ltd - Hy Other Income a$6 Mln

THOMSON REUTERS

Neurizon Therapeutics Ltd - Loss for Half Year Attributable a$5.5 Mln

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/NUZ.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NUZ.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NUZ.AU\",,,,,undefined,":{"symbol":"NUZ.AU","market":"AU","secType":"STK","nameCN":"NEURIZON THERAPEUTICS LTD","latestPrice":0.056,"timestamp":1787897520000,"preClose":0.056,"halted":0,"volume":1066843,"delay":0,"changeRate":0,"nameEN":"NEURIZON THERAPEUTICS LTD","floatShares":351374969,"shares":784215600,"eps":-0.029,"marketStatus":"Market Closed","change":0,"latestTime":"08-28 16:12:00 AEST","open":0.057,"high":0.057,"low":0.056,"amount":60106,"amplitude":0.017857,"askPrice":0.058,"askSize":209823,"bidPrice":0.056,"bidSize":687795,"shortable":3,"etf":0,"ttmEps":-0.029,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1788134400000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.056,"openAndCloseTimeList":[[1787875200000,1787896800000]],"volumeRatio":1.9000788998794356,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"NUZ.AU","preClose":0.056,"auctionPrice":0.057,"auctionVolume":1981,"auction":3,"marketStatus":"盘后竞价","timestamp":1787896800828}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NUZ.AU\",,,,,undefined,":{"symbol":"NUZ.AU","floatShares":351374969,"roa":"-45.31%","roe":"-137.94%","lyrEps":-0.0176,"volumeRatio":1.9000788998794356,"shares":784215600,"dividePrice":0,"high":0.057,"amplitude":0.017857,"preClose":0.056,"low":0.056,"week52Low":0.055,"pbRate":"3.45","psRate":"2.50","week52High":0.165,"institutionHeld":0,"latestPrice":0.056,"committee":0.532489,"eps":-0.029,"divideRate":0,"volume":1066843,"delay":0,"ttmEps":-0.029,"open":0.057,"prevYearClose":0.085,"prevWeekClose":0.06,"prevMonthClose":0.062,"prevQuarterClose":0.06,"fiveDayClose":0.06,"twentyDayClose":0.062,"sixtyDayClose":0.061,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NUZ.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NUZ.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NUZ.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2627025614","title":"Neurizon Therapeutics Ltd - Total Amount to Be Raised Under Entitlement Offer Is ~a$8.5 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2627025614","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627025614?lang=en_us&edition=fundamental","pubTime":"2026-04-16 07:28","pubTimestamp":1776295709,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nFWN40Y0JF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626716701","title":"Neurizon publishes investor deck outlining NUZ-001 ALS program in HEALEY platform trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2626716701","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626716701?lang=en_us&edition=fundamental","pubTime":"2026-04-10 16:01","pubTimestamp":1775808083,"startTime":"0","endTime":"0","summary":"Neurizon outlined progress for lead asset NUZ-001, an oral small molecule being advanced in ALS through Regimen I of HEALEY ALS Platform Trial.Trial timeline targets enrollment completion in Q3-Q4 2026, with topline data expected in Q3 2027.Neurizon flagged supply-chain de-risking via Elanco, with commercial supply agreement execution expected in Q2 2026 and API supply secured to end of HEALEY trial.Cash at Mar. 31, 2026 was AUD 16.7 million, with convertible note debt of AUD 5.6 million, implying net cash of AUD 11.1 million.Capital structure snapshot listed 708,878,681 shares outstanding, with market capitalization of AUD 60.3 million and enterprise value of AUD 49.2 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurizon Th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL2XkZvJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624150551","title":"Neurizon says NUZ-001 preclinical data supports multi-pathway protein clearance in ALS models","url":"https://stock-news.laohu8.com/highlight/detail?id=2624150551","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624150551?lang=en_us&edition=fundamental","pubTime":"2026-04-01 07:19","pubTimestamp":1774999173,"startTime":"0","endTime":"0","summary":"Neurizon reported new preclinical results on April 1, 2026, outlining additional evidence on NUZ-001 biological activity.Data showed NUZ-001 increased multiple protein-clearance processes in human neuronal models, supporting a multi-pathway approach to neurodegenerative disease.Findings strengthened rationale for NUZ-001 development in ALS, where impaired protein clearance is linked to neuronal damage.Neurizon positioned results as supportive of ongoing clinical evaluation of NUZ-001 in HEALEY ALS Platform Trial.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurizon Therapeutics Ltd. published the original content used to generate this news brief on March 31, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDLMHnYb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619484594","title":"Neurizon Therapeutics Chief Executive Officer Resigns, Shares Down 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619484594","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619484594?lang=en_us&edition=fundamental","pubTime":"2026-03-16 08:40","pubTimestamp":1773621622,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics  said Michael Thurn has resigned as managing director and chief executive officer, stepping down from his executive responsibilities from March 16, with his contractual notice period concluding in July 2026, according to a Monday Australian bourse filing.Thurn will continue to serve as a non-executive director until the completion of his notice period, the filing added.The company said Sergio Duchini will assume the role of interim executive chair until a suitable chief executive is appointed, while a global search for a new CEO is underway with the assistance of executive search firm Coulter Partners.The company's shares fell 13% in recent Monday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","LENZ","NUZ.AU","BK7096","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619748557","title":"Neurizon Therapeutics - Sergio Duchini to Assume Role of Executive Chair Until New CEO Appointed","url":"https://stock-news.laohu8.com/highlight/detail?id=2619748557","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619748557?lang=en_us&edition=fundamental","pubTime":"2026-03-16 05:20","pubTimestamp":1773609614,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260315:nFWN40200M:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619572485","title":"Neurizon Therapeutics  - Michael Thurn Resigns as Managing Director and CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2619572485","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619572485?lang=en_us&edition=fundamental","pubTime":"2026-03-16 05:20","pubTimestamp":1773609614,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260315:nFWN40200M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617591498","title":"Neurizon Says Pre-Clinical Data Supports Potential of Drug Candidate for Neurodegenerative Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2617591498","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617591498?lang=en_us&edition=fundamental","pubTime":"2026-03-05 11:30","pubTimestamp":1772681410,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics  said its treatment candidate, NUZ-001, and major active metabolite NUZ-001 sulfone showed in-vivo biological activity, based on data from ongoing pre-clinical studies, according to a Thursday Australian bourse filing.The company is evaluating NUZ-001 in various Huntington's disease models and showed disease-dependent restoration of brain-derived neurotrophic factor levels and enhanced autophagic markers, among others, the filing said.Huntington's disease is a fatal neurodegenerative disorder caused by a mutation in the HTT gene, which produces a toxic form of the huntingtin protein that damages neurons.Drug exposure studies confirmed that both NUZ-001 and NUZ-001 sulfone were readily taken up in zebrafish, with both compounds demonstrating biological activity in vivo, per the filing. The restorative effects of NUZ-001 and NUZ-001 sulfone on brain-derived neurotrophic factor levels were shown to be selective to the HTT knockdown condition and were not observed in ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614132073","title":"Neurizon Doses First Patient With NUZ-001 in HEALEY ALS Platform Trial Regimen I","url":"https://stock-news.laohu8.com/highlight/detail?id=2614132073","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614132073?lang=en_us&edition=fundamental","pubTime":"2026-02-27 04:35","pubTimestamp":1772138102,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics Ltd. reported that the first participant has been enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial for amyotrophic lateral sclerosis. The company said the regimen is a 36-week randomized, double-blind, placebo-controlled adaptive Phase 2/3 study expected to enroll about 160 ALS participants across U.S. clinical sites, with participants randomized 3:1 to daily NUZ-001 at 10 mg/kg or placebo, followed by a 36-week active treatment extension. Neurizon also cited results from its Phase 1 program in 12 people with ALS, stating NUZ-001 was safe and well-tolerated and showed preliminary signals of efficacy, and said enrollment is expected to complete in the second half of calendar year 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL81bnvH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614963773","title":"BUZZ-Australia's Neurizon Therapeutics rises as HY loss narrows, revenue rises","url":"https://stock-news.laohu8.com/highlight/detail?id=2614963773","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614963773?lang=en_us&edition=fundamental","pubTime":"2026-02-25 10:22","pubTimestamp":1771986156,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neurizon Therapeutics rises as HY loss narrows, revenue rises** Shares of Australia's Neurizon Therapeutics NUZ.AX rise as much as 3.1% to A$0.1, their highest level since February 19** Stock on track to record its third straight session of gains, if the trend holds** Biotech company posts HY loss attributable to A$5.5 million , compared with a loss of A$7.3 million in the prior corresponding period** Posts increase in HY revenue to A$6 million from A$1.8 million last year** Stock has risen 14.1% this year, including session moves","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nL4N3ZL06F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614361778","title":"BRIEF-Neurizon Therapeutics Posts Loss For Half Year Attributable Of A$5.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614361778","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614361778?lang=en_us&edition=fundamental","pubTime":"2026-02-25 09:46","pubTimestamp":1771983978,"startTime":"0","endTime":"0","summary":"BRIEF-Neurizon Therapeutics Posts Loss For Half Year Attributable Of A$5.5 MillionFeb 25 (Reuters) - Neurizon Therapeutics Ltd NUZ.AX:LOSS FOR HALF YEAR ATTRIBUTABLE A$5.5 MILLIONHY  OTHER INCOME A$6 MILLIONFurther company coverage: NUZ.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZK1FD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614729197","title":"Neurizon Therapeutics Ltd - Hy  Other Income a$6 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2614729197","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614729197?lang=en_us&edition=fundamental","pubTime":"2026-02-25 06:52","pubTimestamp":1771973552,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nFWN3ZK1FD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614291927","title":"Neurizon Therapeutics Ltd -  Loss for Half Year Attributable a$5.5 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2614291927","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614291927?lang=en_us&edition=fundamental","pubTime":"2026-02-25 06:52","pubTimestamp":1771973552,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nFWN3ZK1FD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":32,"code":"91000000","status":"200"}]}}